Dr. Jay Tiesman is an R&D Senior Director Research Fellow in the Global BioScience Division of The Procter & Gamble Company in Cincinnati, Ohio, USA. He is the Genomics and Multi-Omics Group Leader and, since joining P&G in 1993, has been actively involved in developing genomics and metagenomics capabilities within the Company. He has been particularly interested in the use of these platforms to gain insight into epithelial cell biology. Before joining P&G, he completed postdoctoral training in the laboratory of Dr. Charlie Hart at ZymoGenetics, Inc. in Seattle, Washington. At ZymoGenetics, he pursued research in the field of growth factor signal transduction associated with wound healing and tissue remodeling. He obtained his Ph.D. in Pathology from the University of Nebraska Medical Center in Omaha, Nebraska. In Omaha, he worked in the Laboratory of Dr. Angie Rizzino at the Eppley Cancer Institute, delineating the roles and impact of growth factors on embryonic development. Before joining Dr. Rizzino, he obtained a Bachelor’s degree in Philosophy and Biology at Creighton University in Omaha.
Dr. Tiesman is an acknowledged expert in genomics and microbiome experimental design and has published over 55 articles and book chapters, two of which have earned “Publication of the Year” honors and one of which has earned recognition from the Faculty of 1000. He also speaks extensively at international meetings on the topic of transcriptomics experimental design and is listed on 150 presentations. He collaborates broadly with scientists in academia and the biotechnology industry and has been a member of many academic/governmental/industrial organizations and scientific advisory boards. He serves on the NIST International Microbiome and Multiomics Standards Alliance (IMMSA), the Kisaco Skin Microbiome Advisory Board, and the Microbiology Society Microbiome Safety Working Team. He most recently served as an adjunct professor at The Hong Kong Polytechnic University and currently sits on the Board of Directors of Ischemia Care Diagnostics, LLC and Production Services Unlimited, Inc.
